Biomarker analysis for cancer immunotherapy


Immune response profiling for in vivo mechanism of action studies and subject stratification

Understanding the mechanism of action (MOA) of a candidate compound is a key step in the drug development process. In particular, delineating the MOA of cancer immunotherapeutics relies on the characterization of the anti-tumor immune response within the tumor but also at the periphery. Such ancillary approaches can also support the research of innovative and robust biomarkers, for subject stratification in trials.

Biomarkers quantification in biological samples

 

Our biomarker services include RT-qPCR analysis, explorations of relevant markers in plasma by ELISA, or FACS immunophenotyping of Peripheral Blood Mononulclear Cells (PBMCs), cells recovered from spleen, ganglia, or tumors themselves. This is the ideal complement to fully understand how candidate immunomodulatory drugs impact on the recruitment & functionality of distinctive immune cells, and how they modify the expression/synthesis/secretion of mediators relevant to tumor growth.

CRO services cancer immunotherapy biomarker analysis: anti-CTLA-4 biomarker quantification plasma and dendritic cells

Innovative biomarkers to classify clinical response to anti-CTLA4 in a CT26 tumor-bearing mice model. Mice were challenged with CT26 and exposed to anti-CTLA4 antibody. Dendritic cells (CD11c+) from spleen were recovered and subjected to multiple RT-qPCR analysis to finaly identify a key markers able to distinguish responders and not responders animals. A related marker was also found at plasmatic level, 13 days after tumor cell inoculation.

For an ancillary study design please inquire using the dialog box!

Special focus: Small molecules as innovative tissue biomarkers (IHC analysis)

 

Taking advantage of ImmuSmol specific knowhow in developing antibodies targeting small molecules – for example the metabolites of the Kynurenine pathway –  we offer a unique “small molecule” pathology service for exploring, localizing and quantifying key players of the immuno-editing process in tissue sections & TMAs by Immunohistochemistry (IHC).

Small molecule biomarker analysis using IHC in Tissue MicroArrays

Small molecule biomarker analysis using ImmunoHistoChemistry (IHC) on Tissue MicroArrays (TMA). TMA sections containing a collection of tumor clinical sample spots were processed for IHC procedure using a specific antibody targeting a small molecule of interest (BiomarkerX – DAB staining). Counterstaining was performed with Hematoxylin (Left panel). Image analysis was performed after color deconvolution (Center panel), allowing startification of patients according to the staining intensity. Indeed, patients with “high” staining profile were charcaterized by a favorable clinical outcome when compared to patients with negative or low level of BiomarkerX.

For a custom small molecule pathology service, please inquire using the dialog box!

contact us

 I agree with the use of my personal data for further communications according to explicyte privacy policy